Drug General Information (ID: DDIHYCR4N0)
Drug Name			Toremifene		Drug Info		Hydroflumethiazide		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Diuretics
Structure

Mechanism of Toremifene-Hydroflumethiazide Interaction (Severity Level: Moderate)
Increased risk of hypercalcemia Click to Show/Hide Mechanism Graph
Drug Name		Toremifene				Hydroflumethiazide
Mechanism		Hypercalcemia				Hypercalcemia
Key Mechanism Factor 1
		Factor Name		Hypercalcemia
		Factor Description		Hypercalcemia is a condition in which the calcium level in your blood is above normal. Too much calcium in your blood can weaken your bones, create kidney stones, and interfere with how your heart and brain work.
Mechanism Description		Increased risk of hypercalcemia by the combination of Toremifene and Hydroflumethiazide

Recommended Action
Management		Monitoring of calcium levels is recommended. Toremifene should be discontinued if severe hypercalcemia occurs. Patients should be advised to notify their physician if they experience potential symptoms of hypercalcemia such as lethargy, somnolence, confusion, headache, seizures, ataxia, weakness, muscle pain, irregular heartbeat, anorexia, thirst, or polyuria.

References
1	Product Information. Fareston (toremifene). Schering Laboratories, Kenilworth, NJ.
2	Therapeutic Research Faculty "Natural Medicines Comprehensive Database."